top of page
  • katrina4384

Sage Therapeutics Announces Topline Results from the Phase 2 SURVEYOR Study.

"The study met its primary endpoint, demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD_CAB) composite score at baseline between healthy participants with Huntington's Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or placebo."

192 views0 comments


bottom of page